Biosimilar medicines: Increasing access to modern essential medicines while supporting sustainability of healthcare systems

Abstract

Get full access to this article

View all access options for this article.

References

Putrik, et al. Inequities in access to biologic and synthetic DMARDS across 46 European countries. Ann Rheum Dis 2014; 73: 198–206.

Orlewska, et al. Access to biologic treatment for RA in CEE countries. Med Sci Monit 2011; 17: SR1–SR13.

Quintiles IMS. Market development in Europe and globally, a perspective on biologicals and biosimilars. In: 4th DIA biosimilars conference Europe, Brussels, Belgium, 8–9 November 2016.

IMS Institute. Delivering on the potential of biosimilar medicines – the role of functioning competitive market, www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf (2016, accessed 1 February 2017).

Simon-Kucher and Partners. Payers’ price & market access policies supporting a sustainable biosimilar medicines market, www.medicinesforeurope.com/wp-content/uploads/2016/09/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication.pdf (2016, accessed 1 February 2017).

Razanskaite V and Cummigs F. Biosimilar remicade – the cost savings benefit. Hospital Pharmacy Europe 2005; 80, http://www.hospitalpharmacyeurope.com/featured-articles/biosimilar-remicade%C2%AE-%E2%80%93-cost-saving-benefits.